Phosphatidic acid (PA)

Phosphatidic acid (PA) is a central lipid second messenger and a key intermediate in the biosynthesis of glycerolipids (Wang et al., 2006) [1]. It is primarily generated within the cell by the action of Phospholipase D (PLD) on phosphatidylcholine or by Diacylglycerol kinase (DAGK) on diacylglycerol (Jang et al., 2012) [2]. PA plays a critical role in cell signaling by recruiting and activating various effector proteins, most notably the mechanistic target of rapamycin (mTOR), which is essential for cell growth and proliferation (Foster, 2009) [3]. Beyond signaling, PA influences membrane curvature and vesicular trafficking, including exocytosis and endocytosis (Zeniou-Meyer et al., 2007) [4]. In clinical contexts, elevated PA levels are associated with cancer progression and resistance to therapy, as PA can provide a survival signal that bypasses certain growth factor requirements (Toschi et al., 2009) [5]. Therapeutic strategies often focus on modulating PA levels by inhibiting PLD or DAGK enzymes, with several small-molecule inhibitors currently used in preclinical research (Su et al., 2009) [6]. Because PA is involved in fundamental cellular processes, targeting its production requires careful consideration of potential impacts on global lipid metabolism and membrane integrity.

Other names

1,2-diacyl-sn-glycero-3-phosphatePhosphatidatePAIntracellular phosphatidic acid

Therapeutic modulation of phosphatidic acid typically involves the inhibition of its biosynthetic enzymes, such as Phospholipase D (PLD1/2) or Diacylglycerol kinase (DAGK), to reduce its intracellular concentration and subsequent activation of oncogenic pathways like mTORC1 (Foster, 2009; Su et al., 2009).